The recent recreational use of synthetic cannabinoid ligands, collectively referred to as 'Spice' , has raised concerns about their safety and possible differences in their biological effect(s) from marijuana/Δ 9 -tetrahydrocannabinol (THC). AM2201, a highly efficacious, potent cannabinoid receptor 1 (CB 1 R) agonist, is a recently detected compound in 'Spice' preparations. Furthermore, structural analogs of AM2201 are now being found in 'Spice' . The present studies were conducted to investigate their Δ 9 -THC-like effects using drug (Δ 9 -THC) discrimination in rats. Results show that the tested compounds were potent cannabinergics that generalized to the response to Δ 9 -THC, with AM2201 being most potent, exhibiting a 14-fold potency difference over Δ 9 -THC. The other analogs were between 2.5-fold and 4-fold more potent than THC. Surmountable antagonism of AM2201 with the selective CB 1 R antagonist/inverse agonist rimonabant also established that the discrimination is CB 1 R dependent.
Introduction
Ligands for the endocannabinoid signaling system (ECS) have been investigated for their use in commercial enterprises where synthetic cannabinoids are offered as alternatives to Δ 9 -tetrahydrocannabinol (THC), the main psychotropic component in cannabis preparations (marijuana, hashish etc.) . Structurally dissimilar to THC, most of these compounds have been based on an indole template created to uncover the structural requirements for preferentially activating the two main cloned ECS recognition sites, namely cannabinoid receptor 1 (CB 1 R) and 2 (CB 2 R). Clandestine production has focused on high-affinity CB 1 R ligands, as the desired endpoint of recreational use (high, stoned etc.) is CB 1 R receptormediated. Although these novel compounds were not initially intended for human consumption and their invivo effects were not examined, the plethora of side effects reported in the recent literature has changed this perspective, for example, clinical/emergency reports points at effects not usually associated with cannabis consumption (Monte et al., 2014) . Thus, further in-vivo studies of these compounds are warranted.
Initially, the most commonly detected synthetic cannabinoid was JWH-018/AM678 but, recently, AM2201, a fluorinated analog of JWH-018, has become more prevalent (Wohlfarth et al., 2015) . This pattern of slightly modifying existing drugs to evade drug control legislation is commonly observed (Banister et al., 2015) . Thus, as AM2201 has recently been made illegal, novel synthetic cannabinoids are expected to enter the market, likely including side chain analogs of AM2201, few of which have been researched in the laboratory. This paucity of data needs to be addressed to determine whether these novel compounds exhibit pharmacological/physiological differences from the previously detected 'Spice' compounds. The current study used drug (THC) discrimination to examine the ability of side chain analogs of AM2201 to produce THC-like discriminative stimulus (i.e. 'subjective'-like effects) (Järbe, 2011) .
Materials and methods

Subjects
Adult male Sprague-Dawley rats (N = 12; Taconic Farms, Germantown, New York, USA) were individually housed in a colony room with an average temperature of 22°C and a 12-h light/dark cycle (lights on at 07:00 h; rats were trained and tested during the light phase). Purina Rat Chow was restricted to ∼ 12 g/day, maintaining body weights between 300 and 430 g.
Apparatus
Drug discrimination training and testing were conducted in eight operant chambers (ENV-001), constructed of Plexiglas and aluminum, each equipped with two response levers, house-lights and lever-lights, and a grid floor. Each chamber was enclosed within a sound-attenuating and light-attenuating enclosure equipped with an exhaust fan. Chambers were interfaced (model SG-502) with an IBM-compatible PC (Dell, Round Rock, Texas, USA). Behavioral sessions and data collection were conducted using the Med-PC software program (v. 1.16) provided with the chambers (Med Associates, St Albans, Vermont, USA).
Procedure
The drug discrimination procedure has been described in detail elsewhere (Järbe et al., 2010) . Briefly, food restricted rats were trained to obtain one 45 mg chocolate flavored pellet (BioServe), according to a fixed-ratio 10 schedule of reinforcement (FR-10). The rats were trained in this two-choice task to respond on drug (THC)or vehicle-appropriate levers once daily. The position of drug-appropriate levers was randomly assigned among subjects so that it was to the right of the food cup for half the subjects. Animals were trained to discriminate between THC (3 mg/kg) and vehicle, administered intraperitoneally 20 min before session onset. Presses on the incorrect lever were recorded but had no programmed consequences. The schedule of drug or vehicle administrations was nonsystematic, with no more than two consecutive drug or vehicle trials. To minimize the potential influence of odor cues left in a chamber by a preceding subject (Extance and Goudie, 1981) , the order of drug and vehicle training sessions for animals trained in the same chamber was varied. Twenty-minute sessions were conducted Monday through Friday. The acquisition criterion was selecting the correct lever on at least 8 out of 10 consecutive training days. Correct selection was defined as total presses before the first reinforcement being equal to or less than 14 (i.e. an animal did not press the wrong lever more than four times before pressing 10 times on the injection-appropriate lever).
Once criterion was met, tests occurred on average three times every 2 weeks; on interim days, training sessions were conducted. There was one session per test day. Drug training sessions preceded half the test sessions; the other half were preceded by vehicle training sessions. Tests were conducted only if responding during both the preceding drug and vehicle training sessions met criterion. If not, animals were retrained for at least three sessions before additional testing. During testing, animals were reinforced for 10 presses on either lever, until 20 min had elapsed or six reinforcers had been delivered, whichever occurred first. Doses were examined in a mixed order. For each dose tested, the percentage of responding on the drug-appropriate lever was calculated from the ratio of the number of presses on the THCassociated lever to the total number of lever presses in a test session. Animals receiving at least one reinforcer during the test session were used for this measure. median dose-effect (ED 50 ) estimates were obtained with nonlinear regression after log dose transformation (Prism v. 5; Graphpad Software Inc., La Jolla, California, USA). In addition, response rate was calculated and subjected to one-way analysis of variance. synthesized at the Center for Drug Discovery, Northeastern University (Boston, Massachusetts, USA), according to synthetic schemes outlined elsewhere (Makriyannis and Deng, 2001) . The cannabinergics were initially dissolved in absolute ethanol and the stock solutions kept in a freezer at − 20°C. At the time of usage, appropriate amounts were withdrawn, the ethanol evaporated under a stream of nitrogen, the residue then dissolved (w/v) in an aqueous solution of dimethyl sulfoxide (2%), propylene glycol (4%), and Tween-80 (4%) before a final suspension with saline slowly added just before dosing. Suspensions of rimonabant were prepared the same way, except the compound was not initially dissolved in ethanol. All drugs were administered intraperitoneally in a volume of 2 ml/kg 20 min before session onset. CB 1 R/CB 2 R binding affinity (K i ) estimates for the four test indoles and the generic structural chemotype are shown in Table 1 ; for methods/procedures on estimating binding affinity, see Sharma et al. (2013) .
Results and discussion
All of the tested compounds fully substituted in the THC discrimination at 20 min after administration, with a rank order of potency of fluoro (AM2201) > alkene > cyano = bromo > THC. Table 1 displays ED 50 and the Δ 9 -THC discrimination with AM2201 and analogs Järbe et al. 213 corresponding 95% confidence intervals for the cannabinergic drug discrimination data (Fig. 1) .
The in-vivo potency of AM2201 is similar to previously published work (Gatch and Forster, 2014) . Tetrad data on both the alkene and bromo analogs have been previously reported, and their potencies were comparable with the present bioassay (Wiley et al., 1998; Vigolo et al., 2015) . The prediction that these analogs might enter the clandestine market was recently confirmed as the bromo, chloro and alkene substitution versions have all been detected in batches of 'Spice' in the past year (Simoes et al., 2014; Vigolo et al., 2015) . These analogs are readily synthesized employing the same precursors as those used in creating AM2201 or JWH-018/AM678. Besides being detected in some batches of 'Spice', the alkene analog is also important as it has been identified, along with JWH-018/AM678, as a combustion product of AM2201. This means that people smoking AM2201 may also be inhaling the alkene analog, which appears to be only slightly less potent than AM2201 (Donohue and Steiner, 2012) .
Combinations of AM2201 with a fixed dose of the CB 1 R antagonist/inverse agonist rimonabant produced surmountable antagonism with a 7.87 right-fold difference in potency, supporting the notion of a CB 1 R mechanism for the discrimination. A right-ward shift of this magnitude is consistent with previous antagonism studies involving rimonabant and JWH-018/AM678 as well as THC in drug discrimination (Järbe et al., 2001; Järbe et al., 2011) .
The timecourse of AM2201 shows a behavioral/functional half-life of ∼60 min, which is in accordance with previous data (Gatch and Forster, 2014) . This is also similar to most other reported 'Spice' indole compounds, in which they are shorter acting than THC (e.g. Järbe et al., 2011; Rodriguez and McMahon, 2014) .
Overall, the present drug discrimination data add to the growing number of THC-like compounds identified by this mechanistic in-vivo receptor assay. These new analogs of AM2201 appear to be potent CB 1 R agonists that mimic the discriminative stimulus effects of THC. Both the short duration of action and highly potent nature of AM2201 are common hallmarks of drugs of abuse and, as suggested by recent case-report documentation, highlight the dangers posed by these synthetic cannabinoids (Rodgman et al. 2014) . While this study clearly demonstrates that these compounds produce similar discriminative stimulus effects to THC/marijuana, their high efficacy at CB 1 R compared with THC, and the scant information regarding potential side effects calls for further investigation of their potentially harmful effects.
